Fintel reports that on September 4, 2025, Guggenheim initiated coverage of Summit Therapeutics (BMV:SMMT) with a Buy recommendation.

What are Other Shareholders Doing?

Baker Bros. Advisors holds 33,723K shares representing 40.84% ownership of the company. In its prior filing, the firm reported owning 24,425K shares , representing an increase of 27.57%. The firm increased its portfolio allocation in SMMT by 33.53% over the last quarter.

Price T Rowe Associates holds 3,905K shares representing 4.73% ownership of the company. In its prior filing, the firm reported owning 6,558K shares , representing a decrease of 67.93%. The firm decreased its portfolio allocation in SMMT by 39.60% over the last quarter.

Geode Capital Management holds 2,935K shares representing 3.55% ownership of the company. In its prior filing, the firm reported owning 3,285K shares , representing a decrease of 11.93%. The firm decreased its portfolio allocation in SMMT by 53.39% over the last quarter.

PRHSX - T. Rowe Price Health Sciences Fund holds 2,747K shares representing 3.33% ownership of the company.

IWM - iShares Russell 2000 ETF holds 2,439K shares representing 2.95% ownership of the company. In its prior filing, the firm reported owning 2,486K shares , representing a decrease of 1.92%. The firm increased its portfolio allocation in SMMT by 19.83% over the last quarter.